Table 1 Clinical characteristics of breast cancer patients

Age (year)

 <35

16 (31.00 ± 2.68)

11.3

 35–50

60 (43.20 ± 4.70)

42.2

 >50

66 (57.47 ± 5.19)

46.5

Menopause

 No

83

58.5

 Yes

59

41.5

T-stage

 T0–T2

61

43.0

 T3–T4

81

57.0

N-stage

 N0–N1

43

30.3

 N2–N3

99

69.7

Clinical stage

 I–III

108

76.1

 IV

34

23.9

Molecular subtypes

 Luminal A

10

7.0

 Luminal B

77

54.2

 HER2 + 

33

23.2

 TNBC

22

15.5

Chemotherapy regimen^a

 TEC (docetaxel 75 mg/m², epirubicin 75 mg/m²)

114

80.3

 EC-T/EC-TH (docetaxel 90 mg/m², epirubicin 90 mg/m²)

23

16.2

 TCbH (taxane 175 mg/m²)

3

2.1

 TCb (taxane 175 mg/m²)

1

0.7

 EC (epirubicin 90 mg/m²)

1

0.7